POINT BIOPHARMA GLOBAL INC. Operating Expenses
POINT BIOPHARMA GLOBAL INC. reported Operating Expenses of $32.42 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-11-13
- POINT BIOPHARMA GLOBAL INC. operating expenses for the quarter ending 2023-09-30 was $32.42M, a 31.57% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. operating expenses for the quarter ending 2023-06-30 was $36.36M, a 46.08% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. operating expenses for the quarter ending 2023-03-31 was $31.92M, a 95.73% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. operating expenses for the quarter ending 2022-12-31 was $35.22M, a 149.84% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. operating expenses for fiscal 2022 was $101.06M, a 122.05% increase from fiscal 2021.
- POINT BIOPHARMA GLOBAL INC. operating expenses for fiscal 2021 was $45.51M, a 247.03% increase from fiscal 2020.
- POINT BIOPHARMA GLOBAL INC. operating expenses for fiscal 2020 was $13.11M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-09-30 | $32.42M 10-Q · filed 2023-11-13 | $68.78M derived: sum of 2 quarters · filed 2023-11-13 | $100.70M 10-Q · filed 2023-11-13 | $135.92M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $36.36M 10-Q · filed 2023-08-14 | $68.29M 10-Q · filed 2023-08-14 | $103.50M derived: sum of 3 quarters · filed 2023-08-14 | $128.14M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $31.92M 10-Q · filed 2023-05-15 | $67.14M derived: sum of 2 quarters · filed 2023-05-15 | $91.77M derived: sum of 3 quarters · filed 2023-11-13 | $116.67M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $35.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $59.85M derived: sum of 2 quarters · filed 2023-11-13 | $84.75M derived: sum of 3 quarters · filed 2023-11-13 | $101.06M 10-K · filed 2023-03-27 |
| 2022-09-30 | $24.64M 10-Q · filed 2023-11-13 | $49.53M derived: sum of 2 quarters · filed 2023-11-13 | $65.84M 10-Q · filed 2023-11-13 | $79.94M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $24.89M 10-Q · filed 2023-08-14 | $41.20M 10-Q · filed 2023-08-14 | $55.30M derived: sum of 3 quarters · filed 2023-08-14 | $72.33M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $16.31M 10-Q · filed 2023-05-15 | $30.40M derived: sum of 2 quarters · filed 2023-05-15 | $47.44M derived: sum of 3 quarters · filed 2023-05-15 | $56.09M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $31.13M derived: sum of 2 quarters · filed 2023-03-27 | $39.78M derived: sum of 3 quarters · filed 2023-03-27 | $45.51M 10-K · filed 2023-03-27 |
| 2021-09-30 | $17.03M 10-Q · filed 2022-11-14 | $25.68M derived: sum of 2 quarters · filed 2022-11-14 | $31.42M 10-Q · filed 2022-11-14 | $36.82M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $8.65M 10-Q · filed 2022-08-12 | $14.38M 10-Q · filed 2022-08-12 | $19.79M derived: sum of 3 quarters · filed 2022-08-12 | $22.86M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $5.73M 10-Q · filed 2022-05-13 | $11.14M derived: sum of 2 quarters · filed 2022-05-13 | $14.21M derived: sum of 3 quarters · filed 2022-05-13 | $17.44M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $8.48M derived: sum of 2 quarters · filed 2022-03-25 | $11.71M derived: sum of 3 quarters · filed 2022-03-25 | $13.11M 10-K · filed 2022-03-25 |
| 2020-09-30 | $3.08M 10-Q · filed 2021-11-12 | $6.30M derived: sum of 2 quarters · filed 2021-11-12 | $7.71M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $3.23M 10-Q · filed 2021-08-13 | $4.64M 10-Q · filed 2021-08-13 |